Combination treatments in Alzheimer’s disease: risks and benefits

References

• Minati L, Edginton T, Bruzzone TG, Giaccone G. Current concepts in Alzheimer’s disease: a multidisciplinary review. Am. J. Alzheimers Dis. Other Dement.24(2), 95–121 (2008).
   Google Scholar
• Jalbert JJ, Daiello LA, Lapane KL. Dementia of Alzheimer type. Epidemiol. Rev.30, 15–34 (2008).
   PubMedGoogle Scholar
• Moreira PI, Zhu X, Nunomura A, Smith MA, Perry G. Therapeutic options in Alzheimer’s disease. Expert Rev. Neurother.6(6), 897–910 (2006).
   PubMedGoogle Scholar
• Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr. Alzheimer Res.6(2), 86–96 (2009).
   PubMed Web of Science ®Google Scholar
• Francis PT. Glutamatergic approaches to the treatment of cognitive and behavioral symptoms of Alzheimer’s disease. Neurodegener. Dis.5(3–4), 241–243 (2008).
   PubMedGoogle Scholar
• Pakaski M, Kalman J. Interactions between the amyloid and cholinergic mechanism in Alzheimer’s disease. Neurochem. Int.53(5), 103–111 (2008).
   PubMed Web of Science ®Google Scholar
• Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhitbits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett.566(1–3), 261–269 (2004).
   PubMed Web of Science ®Google Scholar
• Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res. Ther.1(2), 7 (2009).
   PubMed Web of Science ®Google Scholar
• Shanks M, Kivipelto M, Bullock R, Lane R. Cholinesterase inhbition: is there evidence for disease-modifying effects? Curr. Med. Res. Opin.25(10), 2439–2446 (2009).
   PubMed Web of Science ®Google Scholar
• Fox C, Maidment ID, Boustani M, Katona C. Memantine combined with an acetyl cholinesterase inhibitor – hope for the future? Neuropsychiatr. Dis. Treat.2(2), 121–125 (2006).
   PubMedGoogle Scholar
• Vidal JS, Lacombe JM, Dartigues JF et al. Memantine therapy for Alzheimer Disease in real-world practice. An observational study in a large representative sample of French patients. Alzheimer Dis. Assoc. Disord.22(2), 125–130 (2008).
   PubMed Web of Science ®Google Scholar
• Weinstein AM, Barton C, Ross L, Kramer JH, Yaffe K. Treatment practices of mild cognitive impairment in California Alzheimer’s Disease Centers. J. Am. Geriatr. Soc.57(4), 686–690 (2009).
   PubMed Web of Science ®Google Scholar
• Froelich L, Andreasen N, Tsolaki M et al. Long-term treatment of patients with Alzheimer’s disease in primary and secondary care: results from an internationale survey. Curr. Med. Res. Opin.25(12), 3059–3068 (2009).
   PubMed Web of Science ®Google Scholar
• Danysz W, Parsons CG, Moebius HJ, Stoeffer A, Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer’s disease. Neurotox. Res.2(2–3), 85–97 (2000).
   PubMed Web of Science ®Google Scholar
• Zheng F, Johnson SW. Metabotropic glutamate and muscarinic cholinergic receptor-mediated preferential inhibition of N-methyl-D-aspartate component of transmission in rat ventral tegmental area. Neuroscience116(4), 1013–1020 (2003).
   PubMedGoogle Scholar
• Flores-Fernandez J, Salgado H, De La Rosa V et al. Cholinergic direct inhibition of N-methyl-D-aspartate receptor-mediated currents in the rat neocortex. Synapse63(4), 308–318 (2009).
   PubMedGoogle Scholar
• Francis PT. The interplay of neurotransmitters in Alzheimer’s disease. CNS Spectr.10(11 Suppl. 18), 6–9 (2005).
   PubMed Web of Science ®Google Scholar
• Geerts H, Grossberg GT. Pharmacology of acetylcholinestarase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer’s disease. J. Clin. Pharmacol.46(7 Suppl. 1), S8–S16 (2006).
   PubMed Web of Science ®Google Scholar
• Aracava Y, Pereira EF, Maelicke A, Albuquerque EX. Memantine blocks α7* nicotinic acetylcholine receptors more potently than N-methyl-D-aspartate receptors in rat hippocampal neurons. J. Pharmacol. Exp. Ther.312(3), 1195–1205 (2005).
   PubMed Web of Science ®Google Scholar
• Ramnes G, Danysz W, Parsons CG. Pharmacodynamics of memantine: an update. Curr. Neuropharmacol.6(1), 55–78 (2008).
   PubMed Web of Science ®Google Scholar
• Periclou AP, Ventura D, Sherman T, Rao N, Abramowitz WT. Lack of pharmacokinetic interaction between memantine and donepezil. Ann. Pharmacother.38(9), 1389–1394 (2004)
   PubMed Web of Science ®Google Scholar
• Yao C, Raoufinia A, Gold M et al. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J. Clin. Pharmacol.45(5), 519–528 (2005).
   PubMed Web of Science ®Google Scholar
• Shua-Haim J, Smith J, Picard F et al. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer’s disease not affected by co-administration of memantine: an open-label, crossover, single-centre study. Clin. Drug Invest.28(6), 361–374 (2008).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer’s disease already receiving donepezil: a randomized, controlled trial. JAMA291(3), 317–324 (2004).
   PubMed Web of Science ®Google Scholar
• Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT for the Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr. Alzheimer Res.5(1), 83–89 (2008).
   PubMed Web of Science ®Google Scholar
• Olin JT, Bhatnagar V, Reyes P, Koumaras B, Meng X, Brannan S. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int. J. Geriatr. Psychiatry25(4), 419–426 (2010).
   PubMed Web of Science ®Google Scholar
• Farlow MR, Alva G, Meng X, Olin JT. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis. Curr. Med. Res. Opin.26(2), 263–269. (2010).
   PubMed Web of Science ®Google Scholar
• Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer’s disease who failed to benefit from previous cholinesterase inhibitor treatment. Int. J. Clin. Pract.60(1), 110–118 (2006).
   PubMed Web of Science ®Google Scholar
• Pass MD, Shua-Haim JR, Patel P et al. Tolerability and caregiver’s impressions of combination therapy with galantamine and memantine for the treatment of Alzheimer’s disease. Presented at: 8th Alzheimer’s Association International Conference on Alzheimer’s Disease. Chicago, IL, USA, 26–31 July 2008.
   Google Scholar
• Patel S, Shua-Haim JR, Pass MD, Lee P. Safety, tolerability and caregiver’s impressions of combination therapy with donepezil and memantine for the treatment of Alzheimer’s disease. Presented at: 8th Alzheimer’s Association International Conference on Alzheimer’s Disease. Chicago, IL, USA, 26–31 July 2008.
   Google Scholar
• Shua-Haim JR, Pass MD, Patel S et al. Safety, tolerability and caregiver’s impressions of combination therapy with rivastigmine and memantine for the treatment of Alzheimer’s disease. Presented at: 8th Alzheimer’s Association International Conference on Alzheimer’s Disease. Chicago, IL, USA, 26–31 July 2008.
   Google Scholar
• Peters O, Maier W, Luckhaus C et al. Safety and efficacy of galantamine/memantine combination in mild to moderate Alzheimer’s disease – randomized controlled trial. Presented at: 9th Alzheimer’s Association International Conference on Alzheimer’s Disease. Vienna, Austria, 11–16 July 2009.
   Google Scholar
• Cummings JL, Schneider LS, Tariot PN, Graham SM; Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology67(1), 57–63 (2006).
   PubMed Web of Science ®Google Scholar
• van Dyck CH, Schmitt FA, Olin JT. A responder analysis of memantine treatment in patients with Alzheimer’s disease maintained on donepezil. Am. J. Geriatr. Psychiatry14(5), 428–437 (2006).
   PubMed Web of Science ®Google Scholar
• Schmitt FA, van Dyck CH, Wichems CH, Olin JT. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory re-analysis. Alzheimer Dis. Assoc. Disord.20(4), 255–262 (2006).
   PubMed Web of Science ®Google Scholar
• Feldman HH, Schmitt FA, Olin JT. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis. Assoc. Disord.20(4), 263–268 (2006).
   PubMed Web of Science ®Google Scholar
• Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer Disease. Alzheimer Dis. Assoc. Disord.22(3), 209–221 (2008).
   PubMed Web of Science ®Google Scholar
• Lopez OL, Becker JT, Wahed AS et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J. Neurol. Neurosurg. Psychiatry80(6), 600–607 (2009).
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stoeffler A, Schmitt F, Ferris S, Moebius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch. Neurol.63(1), 49–54 (2006).
   PubMed Web of Science ®Google Scholar
• Morris MC. The role of nutrition in Alzheimer’s disease: epidemiological evidence. Eur. J. Neurol.16(Suppl. 1), 1–7 (2009).
   PubMedGoogle Scholar
• Feart C, Samieri C, Rondeau V et al. Adherence to a Mediterrean diet, cognitive decline, and risk of dementia. JAMA302(6), 638–648 (2009).
   PubMed Web of Science ®Google Scholar
• Scarmeas N, Luchsinger JA, Schupf N et al. Physical activity, diet, and risk of Alzheimer disease. JAMA302(6), 627–637 (2009).
   PubMed Web of Science ®Google Scholar
• Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N. Engl. J. Med.336(17), 1216–1222 (1997).
   PubMed Web of Science ®Google Scholar
• Sobow T, Kloszewska I. Donepezil plus vitamin E as a treatment in Alzheimer disease. Alzheimer Dis. Assoc. Disord.17(4), 244 (2003).
   PubMedGoogle Scholar
• Petersen RC, Thomas RG, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med.352(23), 2379–2388 (2005).
   PubMed Web of Science ®Google Scholar
• Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA297(8), 842–857 (2007).
   PubMed Web of Science ®Google Scholar
• Pavlik VN, Doody RS, Rountree SD, Darby EJ. Vitamin E use is associated with improved survival in an Alzheimer’s Disease Cohort. Dement. Geriatr. Cogn. Disord.28(6), 536–540 (2009).
   PubMed Web of Science ®Google Scholar
• Connelly PJ, Prentice NP, Cousland G, Bonham J. A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer’s disease. Int. J. Geriatr. Psychiatry23(2), 155–160 (2008).
   PubMed Web of Science ®Google Scholar
• Aisen PS, Schneider LS, Sano M et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA300(15), 1774–1783 (2008).
   PubMed Web of Science ®Google Scholar
• Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol.63(10), 1402–1408 (2006).
   PubMed Web of Science ®Google Scholar
• Freund-Levi Y, Basun H, Cederholm T et al. Omega-3 supplementation in mild to moderate Alzheimer’s disease: effects on neuropsychiatric symptoms. Int. J. Geriatr. Psychiatry23(2), 161–169 (2008).
   PubMed Web of Science ®Google Scholar
• Magyar K, Palfi M, Jenei V, Szoko E. Deprenyl: from chemical synthesis to neuroprotection. J. Neural Transm. Suppl.71, 143–156 (2006).
   Google Scholar
• Birks J, Flicker L. Selegiline for Alzheimer’s disease. Cochrane Database Syst. Rev.1, CD000442 (2003).
   Google Scholar
• Youdim MB, Bar Am O, Yogev-Falach M et al. Rasagilne: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res.79(1–2), 172–179 (2005).
   PubMed Web of Science ®Google Scholar
• Kelley BJ, Knopman DS. Alternative medicine and Alzheimer’s disease. Neurologist14(5), 299–306 (2008).
   PubMedGoogle Scholar
• Yasui-Furukori N, Furukori H, Kaneda A, Kaneko S, Tateishi T. The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J. Clin. Pharmacol.44(5), 538–542 (2004).
   PubMed Web of Science ®Google Scholar
• Yancheva S, Ihl R, Nikolova G et al. Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer’s disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment. Health13(2), 183–190 (2009).
   PubMed Web of Science ®Google Scholar
• Szekely CA, Town T, Zandi PP. NSAIDs for the chemoprevention of Alzheimer’s diseae. Subcell. Biochem.42, 229–248 (2007).
   PubMedGoogle Scholar
• Henderson VW. Action of estrogens in the aging brain: dementia and cognitive aging. Biochim. Biophys. Acta DOI: 10.1016/j.bbagen.2009.11.005 (2009) (Epub ahead of print).
   Google Scholar
• Rockwood K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer’s disease. Acta Neurol. Scand. Suppl.185, 71–77 (2006).
   PubMedGoogle Scholar
• Kandiah N, Feldman HH. Therapeutic potential of statins in Alzheimer’s disease. J. Neurol. Sci.283(1–2), 230–234 (2008).
   Google Scholar
• De Jong D, Jansen R, Hoefnagels W et al. No effect of one-year treatment with indomethacin on Alzheimer’s disease progression: a randomized controlled trial. PLoS One3(1), e1475 (2008).
   PubMed Web of Science ®Google Scholar
• Reines SA, Block GA, Morris JC et al. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology62(1), 66–71 (2004).
   PubMed Web of Science ®Google Scholar
• Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA289(21), 2819–2826 (2003).
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Black SE, Hendrix SB et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer’s disease: a randomised Phase II trial. Lancet Neurol.7(6), 483–493 (2008).
   PubMed Web of Science ®Google Scholar
• Green RC, Schneider LS, Amato DA et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA302(23), 2557–2564 (2009).
   PubMed Web of Science ®Google Scholar
• Schneider LS, Farlow M. Combined tacrine and estrogen replacement therapy in patients with Alzheimer’s disease. Ann. NY Acad. Sci.826, 317–322 (1997).
   PubMedGoogle Scholar
• Laine K, Palovaara S, Tapanainen P, Manninen P. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy. Clin. Pharmacol. Ther.66(6), 602–608 (1999).
   PubMedGoogle Scholar
• Rigaud AS, Andre G, Vellas B, Touchon J, Pere JJ; French Study Group. No additional benefit of HRT on response to rivastigmine in menopausal women with AD. Neurology60(1), 148–149 (2003).
   PubMed Web of Science ®Google Scholar
• Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A. Re-assessing the relationship between cholesterol, statins and Alzheimer’s disease. Acta Neurol. Scand. Suppl.185, 63–70 (2006).
   PubMedGoogle Scholar
• Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Loez J, Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer’s disease: results of the Alzheimer’s Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol. Scand. Suppl.185, 3–7 (2006).
   PubMedGoogle Scholar
• Jones RW, Kivipelto M, Feldman H et al. The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement.4(2), 145–153 (2008).
   PubMed Web of Science ®Google Scholar
• Flirski M, Sobow T. Biochemical markers and risk factors of Alzheimer’s disease. Curr. Alzheimer Res.2(1), 47–64 (2005).
   PubMedGoogle Scholar
• Cummings JL. Defining and labelling disease-modifying treatments for Alzheimer’s disease. Alzheimers Dement.5(5), 406–418 (2009).
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol.6(8), 734–746 (2007).
   PubMed Web of Science ®Google Scholar
• Lovestone S, Francis P, Kloszewska I et al. AddNeuroMed – the European collaboration for the discovery of novel biomarkers for Alzheimer’s disease. Ann. NY Acad. Sci.1180, 36–46 (2009).
   PubMedGoogle Scholar
• Petersen RC, Aisen PS, Beckett LA et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI). Clinical characterization. Neurology74(3), 201–209 (2010).
   PubMed Web of Science ®Google Scholar
• Jones R, Sheehan B, Phillips P et al. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer’s disease – a multicentre RCT. Trials10, 57 (2009).
   PubMedGoogle Scholar
• Bell KF, Bennett DA, Cuello AC. Paradoxical upregalation of glutamatergic presynaptic boutons during mild cognitive impairment. J. Neurosci.27(40), 20810–20817 (2007).
   Google Scholar
• Sobow T, Kloszewska I. Cholinesterase inhibitors in mild cognitive impairment: a meta-analysis of randomized controlled trials. Neurol. Neurochir. Pol.41(1), 13–21 (2007).
   PubMed Web of Science ®Google Scholar
• Ravaglia G, Forti P, Lucicesare A et al. Plasma tocopherols and risk of cognitive impairment in an elderly Italian cohort. Am. J. Clin. Nutr.87(5), 1306–1313 (2008).
   PubMed Web of Science ®Google Scholar
• Doody RS, Gavrilova SI, Sano M et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled study. Lancet372(9634), 207–215 (2008).
   PubMed Web of Science ®Google Scholar